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Background: Sequential injection chromatography (SIC) is a young, ten years old, separation technique. It was
proposed with the benefits of reagent-saving, rapid analysis, system miniaturization and simplicity. SIC with UV
detection has proven to be efficient mostly for pharmaceutical analysis. In the current study, a stand-alone
multi-wavelength fluorescence (FL) detector was coupled to an SIC system. The hyphenation was exploited
for developing an SIC-FL method for the separation and quantification of amiloride (AML) and furosemide
(FSM) in human urine and tablet formulation.
Results: AML and FSM were detected using excitation maxima at 380 and 270 nm, respectively, and emission maxima
at 413 and 470 nm, respectively. The separation was accomplished in less than 2.0 min into a C18 monolithic column
(50 × 4.6 nm) with a mobile phase containing 25 mmol/L phosphate buffer (pH 4.0): acetonitrile: (35:65, v/v). The
detection limits were found to be 12 and 470 ng/mL for AML and FSM, respectively.
Conclusions: The proposed SIC-FL method features satisfactory sensitivity for AML and FSM in urine samples for the
minimum required performance limits recommended by the World Anti-Doping Agency, besides a downscaled
consumption of reagents and high rapidity for industrial-scale analysis of pharmaceutical preparations.
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Method validationBackground
Furosemide (FSM) is a loop diuretic. It is an anthranilic
acid derivative, which is chemically 4-chloro-N-furfuryl-
5-sulfamoylanthranilic acid (Figure 1a). FSM acts inhibi-
ting the co-transportation of sodium, potassium and
chloride. It further causes the excretion of calcium, mag-
nesium and bicarbonate ions [1,2]. In another context,
amiloride (AML) is chemically N-amidino-3,5-diamino-
6-chloropyrazine-2-carboxamide (Figure 1b). AML, as
another potent loop diuretic, acts primarily by blocking
sodium and chloride reabsorption in the ascending limb
of the loop of Henle. FSM helps to conserve potassium
and minimize the risk of alkalosis. It is also used in the
treatment of oedema associated with hepatic cirrhosis
and congestive heart failure [3,4].* Correspondence: abubakridris@hotmail.com
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distribution, and reproduction in any mediumThe association of AML and FSM furnishes a valuable
natriuretic agent with a diminished kaliuretic effect and
minimizes the risk of alkalosis in the treatment of refrac-
tory oedema associated with hepatic cirrhosis or con-
gestive heart failure [5]. Due to the benefits of their
simultaneous use, AML and FSM are being prepared as
binary dosage forms. Accordingly, the development of
assay methods for those two drugs is desirable for the
purpose of quality control. In this issue, various analyt-
ical techniques were exploited including high perform-
ance liquid chromatography [4,6,7], spectrophotometry
[8-10], fluorometry [2] and electroanalytical [11].
On the other hand, athletes use diuretics, in general, for
flushing previously taken prohibited substances with
forced diuresis [12] to achieve acute weight loss. Hence,
the World Anti-Doping Agency (WADA) prohibits the
use of diuretics [13]. Besides being an ethically condemned
practice, the risk to the athletes’ health has to be consid-
ered since they are generally self-administered in a wrongentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,



















Figure 1 Chemical structures of (a) amiloride and (b) furosemide.
Table 1 Minimum and maximum levels of pH, buffer
concentration and percentage volume of acetonitrile




Buffer concentration (mmol/L) 10 25
Percentage volume of acetonitrile (%) 30 70
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http://journal.chemistrycentral.com/content/7/1/144manner; i.e. overdoses, interactions with other drugs or
even the use of drugs of illicit origin [14-16]. Evidently, a
sensitive and reliable analytical method to determine di-
uretics in urine and/or plasma is a prerequisite in sport ac-
tivities. Toward this end, WADA establishes a minimum
detection capability for testing methods called the Mini-
mum Required Performance Limits (MRPL). This is to en-
sure that all doping control laboratories can report the
presence of prohibited substances uniformly. The limit for
each analyte in the class of diuretics is 250 ng/mL [17,18].
The dominant techniques used for screening diuretics in
control urinalysis are GC and HPLC. However, both tech-
niques have the limitations of the high cost of instrumen-
tation and maintenance. Moreover, other challenges in
GC namely are the low volatility of the compounds and
the necessity of the additional step of derivatization. HPLC
has also the limitation of large consumption of solvent
volumes, which is due to the continuous flow of mobile
phase and large instrumentation dimension.
Recently, sequential injection chromatography (SIC) was
introduced to overcome some challenges in separation
techniques [19]. In principle, the procedure of SIC is based
on a sequential injection, i.e. a discontinuous-flow ap-
proach, of a mobile phase and samples. The separation
process is usually carried out into a monolith column using
programmable miniaturized modules. The association of
the three approaches of the discontinuous-flow approach,
monolith separation column and system miniaturizationrenders SIC procedure simple, rapid and reagent-saving
[20-22]. On the other side, the major limitation of SIC is
the limited pressure of the syringe pump. The maximum is
900 psi. This causes back-pressure in separation column
and hence limits the use of long separation column and
hence reduces the separation capability of many analytes.
However, nineteen chromatographic peaks for amino acids
were observed in an SIC profile in a previous study [23].
Another limitation of SIC is that the limited volume of the
syringe. The commercially available syringe volume is
10 mL, which might not be sufficient for eluting all com-
pounds from a separation column. However, this problem
could be solved by refilling the syringe.
In the current study, a SIC system was coupled with a
fluorescence (FL) detector to provide an analytical method
for the separation and quantification of AML and FSM in
human urine and pharmaceutical formulation. The cap-
abilities of that couple were exploited in terms of reagent-
saving, analysis time, sensitivity and selectivity.
Results and discussion
Method optimization
A short monolith column (50 × 4.6 mm) was examined
and, initially, it has been found to be sufficient for the
separation of the two drugs. With respect to column di-
mension, the practicable flow rate of 20–40 μL/s in SIC
was tested [24-30]. It is well known that high flow rate
accelerates analysis and sharpens peaks. In contrast, high
flow rates increases the back-pressure in a separation
column. Accordingly, the optimum flow rate set in the
current study was 25 μL/s. On the other hand, with re-
spect to peak height and peak shape, the practicable range
of sample volume is 40–60 μL [24-30]. At a large sample
volume, peak height was significantly improved while
acceptable peak shape was not achieved. Hence, the
optimum sample volume has been found to be 30 μL.
For the optimization of mobile phase composition,
acetonitrile, primarily, shows better separation than
methanol. Moreover, phosphate buffer was found be es-
sential for satisfactory separation. The preliminary study
indicated the possible ranges of pH, buffer concentration
and the percentage volume of acetonitrile (Table 1). The
23 full-factorial design was adopted to screen the effect of
those three conditions on resolution, retention time and
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http://journal.chemistrycentral.com/content/7/1/144peak area. UV detection at 380 and 270 nm for AML and
FSM, respectively, was adopted for optimization. There-
after, the optimum conditions were applied for fluores-
cence detection for further studies, namely method
validation and application. The results obtained are com-
piled in Table 2. More than sufficient separation with a
resolution of ≥ 4.5 was obtained at high percentage volume
of acetonitrile and different levels of pH and buffer con-
centration. At those conditions, the retained FSM was
eluted at 0.94 to 2.43 min. Also, relatively, large peak area
of both drugs was obtained at those conditions. In con-
trast, low percentage volume of acetonitrile, with either
high level or low level of pH and buffer concentration, did
not exhibit sufficient separation. Table 2 shows the condi-
tions and results of three additional experiments, which
were carried out with fixing pH and buffer concentration
at their high levels. Table 2 shows that the mobile phase
composition of 25 mmol/L phosphate: acetonitrile (35:65,
v/v) at pH 4.0 achieved more than sufficient separation
with a resolution of 8.2 and short retention times of both
AML and FSM. Additionally, fully symmetrical peak of
AML (1.00) and semi-symmetrical peak of FSM (0.89)
were achieved (Figure 2). Eventually, Table 3 presents the
optimum instrumental and chemical conditions proposed
to the current SIC-FL method.
Method validation
The validation metrics including linearity, recovery and sim-
ple and complex precision as well as the limits of detection
and quantitation were determined from measurements.
For linearity studies, samples were prepared using the
highest calibrators, namely 100 μg/mL AML and 200 μg/mLTable 2 23 full-factorial design matrixa and further
experimentsb for screening the effect of pH buffer
concentration and percentage volume of acetonitrile on
resolution (R), retention time (tR, min) and peak area
pH BCa ACN% R
tR Peak area
AML FSM AML FSM
4.0 25 30 < 1.0 - - - -
4.0 25 70 8.5 0.89 0.95 975161 990962
4.0 10 30 < 1.0 - - - -
4.0 10 70 8.5 0.89 0.94 986511 981150
3.0 25 30 < 1.0 - - - -
3.0 25 70 8.7 2.25 2.37 2908429 6670422
3.0 10 30 < 1.0 - - - -
3.0 10 70 8.2 2.35 2.43 931563 1070808
4.0 25 50 6.9 0.78 1.06 1044527 1072148
4.0 25 60 7.8 0.84 1.20 1007888 750986
4.0 25 65 8.2 0.85 1.62 1032450 901919
athe first eight rows compile the 23 full-factorial design matrix; bthe last three
rows compile further experiments.FSM. Serial dilutions were made to achieve AML con-
centrations of: 0.1, 0.5, 1.0, 2.0, 3.0 and 4.0 μg/mL; and
FSM concentrations of: 2.0, 3.0, 4.0, 6.0, 8.0 and
10.0 μg/mL. Linearity was determined via the least
squares linear regression analysis of the data obtained
from the average of three replicates from each of the
levels described above. A previous spectrofluorimetric
method [5] reported linear ranges of 3.7 × 10-4-0.8 and
1.2 × 10-3-4.0 μg/mL for AML and FSM, respectively.
Despite these ranges are lower than the corresponding
of the current SIC-FL method, the latter are sufficient
for drug detection in urine and more suitable for phar-
maceutical analysis.
Simple (within-run) precision was evaluated through
the analysis of three spiked urine samples, which were
run seven times. The first sample included 0.02 AMLμg/
mL and 0.40 FSMμg/mL. The second sample included
0.03 AMLμg/mL and 0.80 FSMμg/mL. The third sample
included 0.40 AMLμg/mL and 1.20 FSMμg/mL. The
samples were injected into the SIC-FL system after SPE
with a preconcentration factor of 5. Mean and RSD were
assessed at each level. Complex (between-run) precision
for the method was determined through the analysis of
the aforementioned samples injected once per day for
five days. Once again, mean and RSD were evaluated. In
general, Table 4 shows acceptable precision, at its two
levels simple and complex, for both AML and FSM
quantification.
The LOD was determined at a signal-to-noise ratio of
3 whereas the LOQ was determined at a signal-to-noise
ratio of 10. The noise was assessed using drug-free hu-
man urine samples after SPE. Interestingly, the LOQs of
AML and FSM (Table 4) achieved from the current SIC-
FL match the MRPL that was recommended by WADA
[17,18]. A previous HPLC screening test was presented
for some diuretics of doping interest in human urine
[16]. In that method, the LOD for AML and FSM were
0.750 and 0.125 μg/mL, respectively. These levels are
not in consistence with the current SIC-FL method. This
could be attributed to the use of liquid-liquid extraction
for sample treatment and UV for the detection in the
previous HPLC method [16] while SPE and fluorescence
detection were used in the current SIC method.
Method application
The proposed SIC-FL method was applied to four urine
samples. All samples were subjected to SPE. One sample
was free from AML and FSM in order to examine the
efficiency of SPE for sample clean-up and to calculate
the LODs and LOQs. The chromatogram of one sample
as an example is depicted in Figure 2a. Acceptable base-
line was obtained indicating acceptable efficiency of the
sample clean-up step in the adopted SPE procedure [31].
The other samples were spiked with different quantities
Figure 2 SIC profiles following fluorescence of: (a) urine sample after solid-phase extraction and (b) urine sample spiked with (1)
amiloride and (2) furosemide to get concentration of 3.0 μg/mL of each drug.
Table 3 Optimal analytical conditions of the SIC-FL method
Analytical character AML FSM
Separation column (50 × 4.6 mm)
Mobile phase composition 25 mm phosphate : acetonitrile
(35:65 v/v, pH 4.0)
Sample volume (μL) 30
Flow rate (μL/s) 25
Excitation wavelength (nm) 380 270
Emission wavelength (nm) 413 470
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“Method validation”. As an example, Figure 2b shows the
chromatogram of 3.0 μg/mL AML and FSM in a urine
sample. The pre-concentration factor obtained from SPE
was 5. Hence, the level of AML and FSM injected into the
SIC-FL system was 0.6 μg/mL. The recovery obtained
(Table 4) was acceptable indicating the accuracy of the
SPE procedure [31] and the proposed SIC-FL method.
The SIC-FL method was also applied to tablet formu-
lation using three levels of AML and FSM as discussed
in the section entitled “Preparation of reagents and sam-
ples”. As an example, Figure 3 shows an SIC profile of






Total analysis time (min) 4.7
Sample frequency (samples/h) 13
AML FSM
Retention time (min) 0.85 1.62
Peak symmetry 1.00 0.89
Theoretical plates 671.55 937.95
Regression equation PAa = 1.6387Cb +
566.28
PAa = 26.667Cb +
23.333
Correlation coefficient 0.9971 0.9987
Linear range (μg/mL) 0.1-4.0 2.0-10.0
Within-run precision (RSD, %) 1.98 2.02
Between-run precision (RSD, %) 0.57 2.81
Recovery in urine samples (%) 89 91
Recovery in tablets (%) 99.1 for 1.0 μg/mL 98.7 for 8.0 μg/mL
97.5 for 0.5 μg/mL 98.1 for 4.0 μg/mL
97.0 for 0.5 μg/mL 96.5 for 0.5 μg/mL
LOD (μg/mL) 0.012 0.470
LOQ (μg/mL) 0.060 1.500
apeak area; bconcentration (μg/mL)
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Frumil® Tablets. In general, the chromatograms obtained
indicate the applicability of the SIC-FL method to the
separation and quantification of AML and FSM to both
urine samples and tablet formulation.Figure 3 SIC profile following fluorescence of (1) 0.5 μg/mL AML andUnique SIC analytical features
One of the interesting advantages of the proposed SIC-
FL method over HPLC methods is mainly the reagent-
consumption. The total volume of the consumed re-
agent, i.e. mobile phase for column conditioning and
separation, was 4.5 mL. Hence, in routine analysis, SIC
consumes milliters per day versus centiliters per day for
HPLC. As previously mentioned, the reduction of re-
agent consumption in SIC is due to the discontinuous-
flow, downscaled-dimension of instrumentation and the
use of monolithic column. Accordingly, the waste pro-
duction of SIC is less than that of HPLC and hence the
frontal is greener than the latter. On the other side, the
use of monolithic column and the miniaturization of
SIC work hand in hand to provide a rapid analysis. The
total analysis time including column conditioning and
elution, without SPE, was 4.7 min. Hence, the sample
frequency was 13 samples/h. Furthermore, the instru-
mentation simplicity of SIC offers less instrumentation
cost. In addition, the simplicity in SIC instrumentation
makes its maintenance cost less.Experimental
Instrumentation
The SIC system used in the current study was SIChrom®.
It was assembled by FIALab® (Medina, WA US). The
SIC system (Figure 4) included syringe pump (SP), selec-
tion valve (SV), and tubings. The SV was 10 T-0179H
Cheminert® high-pressure stainless-steel (up to 5000 psi)
with 10 ports. It was manufactured by Valco Instrument












































Figure 4 Schematic diagram of sequential injection chromatograph coupled with fluorescence detector constructed for the separation
and quantification of amiloride and furosemide.
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gineering (Pocasset, MA, US). Pump tubing of 0.03" I.D.
Teflon type was supplied from Upchurch Scientific, Inc.
(Oak Harbor, WA, USA). It was used to connect various
devices of the SIC manifold and to make a holing coil
(200 cm long). (vi) PC equipped with FIALab Software®
for Windows® version 5.9 was supplied from FIAlab
(Medina, WA, USA).
The detector was 2475 Multi λ Florescence Detector
from Waters (Milford, CT, US). The light source was a
xenon lamb with excitation wavelength in the range of
200–900 nm. The detector was equipped with excitation
and emission monochromators.
The solid phase extraction (SPE) columns of 6-mL
size, which were used for urine sample treatment, were
Discovery DSC-18. They were supplied by Supleco
(Bellefonte, PA, US).
Chemicals, reagents and samples
Double-distilled deionized water was used throughout
the experimental work. All chemicals and reagents were
of analytical reagent grade. AML hydrochloride hydrate,
FSM, acetonitrile, sodium hydrogen phosphate, ortho-
phosphoric acid were purchased from Sigma-Aldrich
(Taufkirchen, Germany).
Preparation of reagents and samples
100 μg/mL of AML and 200 μg/mL of FSM as stock
standard solutions were prepared by dissolving appropri-
ate amounts in mobile phase. Working standard solu-
tions were prepared by dilution in an appropriate way.
10 mL of urine samples were obtained from eight
healthy volunteers. All samples were filtered through
Whatman® paper No 1. Two samples were then subjected
directly to SPE without spiking drugs. The other samples
were spiked in duplicate with three concentrations of each
drug as described in the subsection entitled “Method val-
idation”. Thereafter, the three replicate samples weresubjected to SPE. 2.5 mL of urine were cleaned through
the SPE columns by 3 mL of water and eluted with 2 mL
of methanol. The methanolic extract was evaporated to
dryness under nitrogen stream and reconstituted in
2 mL mobile phase. Blank urine was treated in same
manner [31].
Frumil® tablets (5 mg of AML hydrochloride and
40 mg of FSM), which were prepared by Sanofi-Aventis
(Dublin, Ireland), were examined. Twenty tablets were
accurately weighed and finely powdered. Three portions
were accurately weighed and transferred into 100-mL
calibrated flasks. The first portion was equivalent to
5 mg of AML and 40 mg of FSM. The second portion
was equivalent to 2.5 mg of AML and 20 mg of FSM.
The third portion was equivalent to 1.25 mg of AML
and 10 mg of FSM. The drugs were extracted by the mo-
bile phase with shaking and filtration. The solutions
were diluted fifty-times. The recovery in tablet formula-
tion was examined using a previous HPLC method as a
reference [4].SIC procedure
A rapid protocol controlling the proposed SIC proced-
ure was programmed. 1.0 mL of the mobile phase was
aspirated through the check valve in the syringe pump
at a flow rate of 150 μL/s. For column conditioning, the
mobile phase was introduced into the separation column
through port-2 and the guard column (Figure 4) at a
flow rate of 30 μL/s. The syringe was filled again with
3500 μL of the mobile phase at a flow rate of 150 μL/s.
30 μL of standards/samples were loaded into the holding
coil through port-3 to port-10 at a flow rate of 10 μL/s.
The sample and mobile phase were then injected into
the guard and separation columns through port-2 at a
flow rate of 25 μL/s. During this step, the fluorescence
detector was set at excitation and emission wavelengths
as presented in Table 3.
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A fluorescence detector was hyphenated to an SIC sys-
tem to generate a sensitive and direct method for the
separation and quantification of AML and FSM. The hy-
phenation also permitted a simple, inexpensive, rapid
and reagent-saving procedure. The SIC-FL method was
validated and it demonstrated to be reliable for the de-
termination of both drugs, being linear, accurate and
precise. Therefore, the SIC-FL method can be consid-
ered suitable for the quantification of both drugs in hu-
man urine samples. The SIC-FL method is also thought
to be ideally suited for a rapid routine analysis for the
quality control of pharmaceutical products.
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